InxMed is a clinical-stage biotech company focus on “Best-in-Disease Combination Strategy”. With disease biology as the source of innovation, InxMed is committed to building a platform with fast clinical transformation and proof-of-concept capability, and becoming a global leading company from China in the 2.0 era of new drug R&D. Established at the end of 2018, InxMed has raised tens of millions of dollars in the completed series A round of funding, established an integrated international advanced R&D and clinical team across Shanghai, Beijing, the United States and Australia in just over half a year, and built cooperative partnerships with well-known MNC companies including Roche.
Members of the InxMed core team have held senior R&D and management positions in top-ranking MNC companies such as Roche, Novartis, MSD, Schering-Plough, GlaxoSmithKline and Johnson & Johnson, who led teams to complete clinical development and registration of a dozen drugs, including Keytruda, Gardasil in China, having rich experience in all aspects of innovative drug research, development, clinical transformation, proof-of-concept, and marketing. We have preliminarily established a series of development pipeline of significant clinical value and synergistic effects which consist of “First-in-Class” and “Best-in-Disease Combination Strategy” drugs. We always actively seek opportunities of licensing-out or collaborative development to maximize the enrichment and optimization of product combination and bring significant medical value for patients.